ProRx LLC has recalled 16,604 vials of compounded injectable medications, including Semaglutide (often used for weight loss or diabetes) and Tirzepatide, because they may not be sterile. The recall involves various doses and sizes, including versions combined with Vitamin B12 (Cyanocobalamin). Using a non-sterile injectable drug can lead to serious or life-threatening infections. Consumers who have used these medications and have concerns should contact their doctor or pharmacist immediately.
A lack of assurance of sterility means the products could be contaminated with microorganisms such as bacteria or fungi. Injecting a contaminated product directly into the body can cause severe infections at the injection site or throughout the bloodstream.
You have 2 options:
Recall #: D-0650-2024; Quantity: 2,490 vials
Recall #: D-0651-2024; Quantity: 37 vials
Recall #: D-0652-2024; Quantity: 8,396 vials
Recall #: D-0653-2024; Quantity: 1,960 vials
Recall #: D-0654-2024; Quantity: 500 vials
Recall #: D-0655-2024; Quantity: 1,489 vials
Recall #: D-0656-2024; Quantity: 1,732 vials
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.